{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:30:30Z","timestamp":1778085030614,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2014M3C7A1064752, MRC2014009392"],"award-info":[{"award-number":["2014M3C7A1064752, MRC2014009392"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["MRC2014009392"],"award-info":[{"award-number":["MRC2014009392"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["MRC2014009392"],"award-info":[{"award-number":["MRC2014009392"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["MRC2014009392"],"award-info":[{"award-number":["MRC2014009392"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2014M3C7A1064752"],"award-info":[{"award-number":["2014M3C7A1064752"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) cerebrospinal fluid (CSF) biomarker cutoffs from immunoassays with low interlaboratory variability in diverse ethnic groups are necessary for their use in clinics and clinical trials. With lack of cutoffs from fully automated immunoassay platforms in diverse races, the aim of this study is to evaluate the clinical utility of CSF AD biomarkers from the Lumipulse fully automated immunoassay based on \u03b2-amyloid (A\u03b2) positron emission tomography (PET) status comparing with these from two manual immunoassays, in Koreans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Among 331 Korean participants enrolled from a prospective, 3-year longitudinal observational study of the validation cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD, 139 (29 CN, 58 SCD, 29 MCI, and 23 AD) provided CSF and 271 underwent baseline amyloid PET (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009128 with overlapping CSF and A\u03b2-PET, and 143 without CSFs). Three annual cognitive and neuropsychiatric function tests were conducted. A\u03b242, A\u03b240, total-tau, and phosphorylated-tau\n                      <jats:sub>181<\/jats:sub>\n                      were measured by Lumipulse fully automated immunoassay and two manual immunoassays (INNO-BIA AlzBio3, INNOTEST). Clinical utility of CSF biomarker cutoffs, based on 128 participants with A\u03b2-PET, was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cognitive and neuropsychological scores differed significantly among the groups, with descending performance among CN&gt;SCD&gt;MCI&gt;AD. Biomarker levels among immunoassays were strongly intercorrelated. We determined the A\u03b2-PET status in a subgroup without CSF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009143), and then when we applied CSF biomarker cutoffs determined based on the A\u03b2-PET status, the CSF biomarkers (cutoffs of 642.1\u2009pg\/mL for A\u03b242, 0.060 for A\u03b242\/A\u03b240, 0.315 for t-tau\/A\u03b242, and 0.051 for p-tau\/A\u03b242, respectively) showed good agreement with A\u03b2-PET (overall AUC ranges of 0.840\u20130.898). Use of the A\u03b2-PET-based CSF cutoffs showed excellent diagnostic discrimination between AD and CN (A\u03b242, A\u03b242\/A\u03b240, t-tau\/A\u03b242, and p-tau\/A\u03b242) with overall AUC ranges of 0.876\u20130.952. During follow-up, participants with AD-like CSF signature determined by A\u03b2-PET-based cutoffs from Lumipulse showed rapid progression of cognitive decline in 139 subjects, after adjustment for potential confounders, compared with those with a normal CSF signature.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CSF AD biomarkers measured by different immunoassay platforms show strong intercorrelated agreement with A\u03b2-PET in Koreans. The Korean-specific A\u03b2-PET-based CSF biomarker cutoffs measured by the Lumipulse assay strongly predicts progression of cognitive decline. The clinical utility of CSF biomarkers from fully-automated immunoassay platforms should be evaluated in larger, more diverse cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00767-3","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T07:12:36Z","timestamp":1610435556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Alzheimer\u2019s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans"],"prefix":"10.1186","volume":"13","author":[{"given":"Sohee","family":"Moon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakulrat","family":"Mankhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Hye","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu","family":"Vandijck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Kostanjevecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Won","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bora","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5235-8993","authenticated-orcid":false,"given":"Ju-Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"issue":"3","key":"767_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"767_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H. Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643\u201363.","journal-title":"J Intern Med"},{"issue":"2","key":"767_CR3","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","volume":"51","author":"A Olsson","year":"2005","unstructured":"Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336\u201345.","journal-title":"Clin Chem"},{"issue":"6","key":"767_CR4","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1373\/clinchem.2013.202937","volume":"59","author":"JH Kang","year":"2013","unstructured":"Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta(1-42) and tau proteins as Alzheimer disease biomarkers. Clin Chem. 2013;59(6):903\u201316.","journal-title":"Clin Chem"},{"issue":"8","key":"767_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1001\/archneurol.2012.26","volume":"69","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, et al. Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol. 2012;69(8):1018\u201325.","journal-title":"Arch Neurol"},{"issue":"9","key":"767_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/archneurol.2011.105","volume":"68","author":"AM Fagan","year":"2011","unstructured":"Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, et al. Comparison of analytical platforms for cerebrospinal fluid measures of beta-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011;68(9):1137\u201344.","journal-title":"Arch Neurol"},{"issue":"5","key":"767_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00401-011-0808-0","volume":"121","author":"LM Shaw","year":"2011","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121(5):597\u2013609.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"767_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jalz.2011.05.2243","volume":"7","author":"N Mattsson","year":"2011","unstructured":"Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer\u2019s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7(4):386\u201395 e6.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"767_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jalz.2013.01.010","volume":"9","author":"N Mattsson","year":"2013","unstructured":"Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer\u2019s Association quality control program. Alzheimers Dement. 2013;9(3):251\u201361.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"767_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Mikulskis A, Fagan AM, Teunissen C, Zetterberg H, Vanderstichele H, et al. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer\u2019s disease diagnosis: a review. Alzheimers Dement. 2018;14(10):1313\u201333.","journal-title":"Alzheimers Dement"},{"key":"767_CR11","doi-asserted-by":"publisher","first-page":"P209","DOI":"10.1016\/j.jalz.2013.05.389","volume":"9","author":"M Vandijck","year":"2013","unstructured":"Vandijck M, Kuwano R, Waligorska T, De Smet S, Tsukie T, Verdoodt L, et al. P1-166: inter-laboratory variation when using a unified test procedure for INNO-BIA AlzBio3. Alzheimers Dement. 2013;9:P209\u2013P10.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"767_CR12","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1515\/cclm-2015-0733","volume":"54","author":"M Bjerke","year":"2016","unstructured":"Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, et al. Assessing the commutability of reference material formats for the harmonization of amyloid-beta measurements. Clin Chem Lab Med. 2016;54(7):1177\u201391.","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"767_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jalz.2015.09.009","volume":"12","author":"T Bittner","year":"2016","unstructured":"Bittner T, Zetterberg H, Teunissen CE, Ostlund RE Jr, Militello M, Andreasson U, et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. Alzheimers Dement. 2016;12(5):517\u201326.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"767_CR14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/alz.12000","volume":"16","author":"J Kaplow","year":"2020","unstructured":"Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham CJ, et al. Concordance of Lumipulse cerebrospinal fluid t-tau\/Abeta42 ratio with amyloid PET status. Alzheimers Dement. 2020;16(1):144\u201352.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"767_CR15","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492\u2013501.","journal-title":"JAMA Neurol."},{"issue":"11","key":"767_CR16","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470\u201381.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"767_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.15430\/JCP.2019.24.2.72","volume":"24","author":"DY Lee","year":"2019","unstructured":"Lee DY, Kim EH. Therapeutic effects of amino acids in liver diseases: current studies and future perspectives. J Cancer Prev. 2019;24(2):72\u20138.","journal-title":"J Cancer Prev"},{"issue":"42","key":"767_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017594","volume":"98","author":"SH Choi","year":"2019","unstructured":"Choi SH, Jung YK, Jang JA, Han S. Idiopathic pulmonary arterial hypertension associated with a novel frameshift mutation in the bone morphogenetic protein receptor II gene and enhanced bone morphogenetic protein signaling: a case report. Medicine (Baltimore). 2019;98(42):e17594.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"767_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1159\/000205512","volume":"27","author":"JC Youn","year":"2009","unstructured":"Youn JC, Kim KW, Lee DY, Jhoo JH, Lee SB, Park JH, et al. Development of the subjective memory complaints questionnaire. Dement Geriatr Cogn Disord. 2009;27(4):310\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"767_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403\u201313.","journal-title":"Ann Neurol"},{"issue":"4","key":"767_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/00365513.2020.1740939","volume":"80","author":"L Agnello","year":"2020","unstructured":"Agnello L, Piccoli T, Vidali M, Cuffaro L, Lo Sasso B, Iacolino G, et al. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. Scand J Clin Lab Invest. 2020;80(4):313\u20137.","journal-title":"Scand J Clin Lab Invest"},{"issue":"9","key":"767_CR22","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1007\/s00415-019-09418-6","volume":"266","author":"JL Bayart","year":"2019","unstructured":"Bayart JL, Hanseeuw B, Ivanoiu A, van Pesch V. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Abeta42 and T-Tau assays for Alzheimer\u2019s disease diagnosis. J Neurol. 2019;266(9):2304\u201311.","journal-title":"J Neurol"},{"issue":"1","key":"767_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"MJ Leitao","year":"2019","unstructured":"Leitao MJ, Silva-Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N, et al. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11(1):91.","journal-title":"Alzheimers Res Ther"},{"issue":"Pt 3","key":"767_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/brain\/awm336","volume":"131","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer\u2019s disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665\u201380.","journal-title":"Brain."},{"key":"767_CR25","doi-asserted-by":"crossref","unstructured":"Hwang J, Jeong JH, Yoon SJ, Park KW, Kim EJ, Yoon B, et al. Clinical and biomarker characteristics according to clinical spectrum of Alzheimer\u2019s disease (AD) in the validation cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD. J Clin Med. 2019;8(3):341.","DOI":"10.3390\/jcm8030341"},{"issue":"11","key":"767_CR26","first-page":"709","volume":"21","author":"H Passing","year":"1983","unstructured":"Passing H. Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J Clin Chem Clin Biochem. 1983;21(11):709\u201320.","journal-title":"J Clin Chem Clin Biochem"},{"issue":"4","key":"767_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ymeth.2012.03.023","volume":"56","author":"JH Kang","year":"2012","unstructured":"Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer\u2019s disease. Methods. 2012;56(4):484\u201393.","journal-title":"Methods."},{"issue":"9251","key":"767_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(00)03589-3","volume":"357","author":"Neuropathology Group. Medical Research Council Cognitive F, Aging S","year":"2001","unstructured":"Neuropathology Group. Medical Research Council Cognitive F, Aging S. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357(9251):169\u201375.","journal-title":"Lancet"},{"issue":"5","key":"767_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","volume":"36","author":"K Blennow","year":"2015","unstructured":"Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer\u2019s disease. Trends Pharmacol Sci. 2015;36(5):297\u2013309.","journal-title":"Trends Pharmacol Sci"},{"issue":"19","key":"767_CR30","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939\u201349.","journal-title":"JAMA."},{"issue":"Suppl 1","key":"767_CR31","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.neurobiolaging.2011.09.006","volume":"32","author":"WE Klunk","year":"2011","unstructured":"Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32(Suppl 1):S20\u201336.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"767_CR32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1212\/WNL.0000000000000032","volume":"82","author":"P Sanchez-Juan","year":"2014","unstructured":"Sanchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014;82(3):230\u20138.","journal-title":"Neurology."},{"issue":"4","key":"767_CR33","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9(4):414\u201321.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"767_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1212\/WNL.0000000000002081","volume":"86","author":"MD Zwan","year":"2016","unstructured":"Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleo A, Herukka SK, et al. Use of amyloid-PET to determine cutpoints for CSF markers: a multicenter study. Neurology. 2016;86(1):50\u20138.","journal-title":"Neurology."},{"issue":"6","key":"767_CR35","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1161\/HYPERTENSIONAHA.117.09097","volume":"69","author":"T Ohkuma","year":"2017","unstructured":"Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, et al. Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease: an individual participant data meta-analysis. Hypertension. 2017;69(6):1045\u201352.","journal-title":"Hypertension."},{"issue":"2","key":"767_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","volume":"56","author":"C Mulder","year":"2010","unstructured":"Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, et al. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem. 2010;56(2):248\u201353.","journal-title":"Clin Chem"},{"issue":"4","key":"767_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385\u201393.","journal-title":"JAMA."},{"issue":"1","key":"767_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/WAD.0000000000000184","volume":"31","author":"SA Park","year":"2017","unstructured":"Park SA, Chae WS, Kim HJ, Shin HS, Kim S, Im JY, et al. Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease in South Korea. Alzheimer Dis Assoc Disord. 2017;31(1):13\u20138.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"9","key":"767_CR39","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, Pegueroles J, Munoz L, Camacho V, Lopez-Mora D, Fernandez-Leon A, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on Lumipulse. Ann Clin Transl Neurol. 2019;6(9):1815\u201324.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"767_CR40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaneurol.2018.4249","volume":"76","author":"JC Morris","year":"2019","unstructured":"Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, et al. Assessment of racial disparities in biomarkers for Alzheimer disease. JAMA Neurol. 2019;76(3):264\u201373.","journal-title":"JAMA Neurol"},{"issue":"12","key":"767_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.17363","volume":"2","author":"SL Garrett","year":"2019","unstructured":"Garrett SL, McDaniel D, Obideen M, Trammell AR, Shaw LM, Goldstein FC, et al. Racial disparity in cerebrospinal fluid amyloid and tau biomarkers and associated cutoffs for mild cognitive impairment. JAMA Netw Open. 2019;2(12):e1917363.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"767_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13195-018-0463-y","volume":"11","author":"S Wolfsgruber","year":"2019","unstructured":"Wolfsgruber S, Molinuevo JL, Wagner M, Teunissen CE, Rami L, Coll-Padros N, et al. Prevalence of abnormal Alzheimer\u2019s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimers Res Ther. 2019;11(1):8.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"767_CR43","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/archneur.55.7.937","volume":"55","author":"D Galasko","year":"1998","unstructured":"Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55(7):937\u201345.","journal-title":"Arch Neurol"},{"issue":"5","key":"767_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.24921","volume":"81","author":"BM Tijms","year":"2017","unstructured":"Tijms BM, Bertens D, Slot RE, Gouw AA, Teunissen CE, Scheltens P, et al. Low normal cerebrospinal fluid Abeta42 levels predict clinical progression in nondemented subjects. Ann Neurol. 2017;81(5):749\u201353.","journal-title":"Ann Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00767-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00767-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00767-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T13:41:12Z","timestamp":1610458872000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00767-3"}},"subtitle":["CSF AD biomarkers measured by Lumipulse in Koreans"],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00767-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-88942\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"26 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was given by the Institutional Review Board of each center (INHAUH 2015-03-021). All participants or their legal representatives voluntarily agreed to participate and provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no disclosure for any conflicts of interest, including financial interests, relationships, activities, and affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}